Mounjaro Doses: The Six Strengths, the Standard Titration Schedule, and How Providers Move You Up

Key Takeaways

• Mounjaro is available in six fixed weekly doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.
• The standard titration starts at 2.5 mg for four weeks, then 5 mg, with optional 2.5 mg increments every four weeks if blood sugar control needs improvement.
• Maximum dose is 15 mg weekly.
• Mounjaro (tirzepatide) comes in six fixed-dose single-use pens.
• Each pen delivers one weekly subcutaneous injection.

Direct answer (40-60 words)

Mounjaro is available in six fixed weekly doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The standard titration starts at 2.5 mg for four weeks, then 5 mg, with optional 2.5 mg increments every four weeks if blood sugar control needs improvement. Maximum dose is 15 mg weekly.

Table of contents

1. The six Mounjaro doses at a glance
2. The official titration schedule
3. What each dose is for
4. Why Mounjaro is titrated, not started full strength
5. How providers decide when to move you up
6. Side effects by dose
7. What the SURMOUNT and SURPASS trials showed at each dose
8. When to slow down or hold a dose
9. Mounjaro doses for type 2 diabetes vs. weight loss
10. Compounded tirzepatide and how its doses compare
11. FAQ
12. Author note and disclaimers

The six Mounjaro doses at a glance

Mounjaro (tirzepatide) comes in six fixed-dose single-use pens. Each pen delivers one weekly subcutaneous injection.

The 2.5 mg pen is intentionally subtherapeutic. Most patients will not see meaningful weight or A1C change at this strength. It exists to let your gut acclimate before the first effective dose at 5 mg.

The official titration schedule

Eli Lilly's prescribing information lays out a specific four-week step-up cadence. Most providers follow it closely.

A patient does not have to climb all six rungs. Many people stay at 5 mg or 10 mg long-term because their blood sugar or weight target is met. Others go straight to 15 mg over five months because their response at lower doses is small.

The four-week minimum at each dose is not arbitrary. Tirzepatide's half-life is roughly 5 days, and steady-state plasma levels take about four to five weeks to stabilize at any given dose. Moving up before steady state means you're chasing side effects without seeing the full clinical benefit of the current step.

What each dose is for

2.5 mg. A primer dose. SURPASS-1 (Rosenstock et al., The Lancet, 2021) and SURMOUNT-1 (Jastreboff et al., NEJM, 2022) both used 2.5 mg as a four-week run-in, not a treatment dose. Expect mild appetite suppression at most.

5 mg. The first dose with a real clinical signal. In SURMOUNT-1, the 5 mg arm achieved 16.0% mean weight loss at 72 weeks. In SURPASS-2, A1C dropped 2.01 points from baseline. This is the dose where many patients decide whether tirzepatide is working for them.

7.5 mg. A bridge dose. Not heavily studied as a final maintenance strength, since most trials skipped it. It's used when a patient tolerates 5 mg well and needs a bit more glycemic or weight effect, or when going straight to 10 mg produces unacceptable nausea.

10 mg. A common long-term dose. SURMOUNT-1 showed 21.4% mean body weight loss at 72 weeks. SURPASS-2 showed an A1C reduction of 2.24 points. For many patients this is the maintenance sweet spot.

12.5 mg. Another bridge. Same logic as 7.5 mg, used to ease the transition between 10 mg and 15 mg.

15 mg. Maximum. SURMOUNT-1 showed 22.5% mean body weight loss at 72 weeks. SURPASS-2 showed an A1C reduction of 2.30 points. The marginal gain over 10 mg is real but smaller than the gain from going from 5 mg to 10 mg.

Why Mounjaro is titrated, not started full strength

Tirzepatide activates two gut hormone receptors, GLP-1 and GIP. Both slow gastric emptying. Start someone at 15 mg and they'll spend the next two weeks vomiting. Start them at 2.5 mg and the gut has time to adapt before each step up.

The four-week titration was chosen during phase 2 trials because shorter intervals produced higher dropout rates from nausea, and longer intervals delayed therapeutic effect without improving tolerability. Four weeks is the published trade-off.

If you experience moderate to severe GI side effects at a new dose, your provider can hold you at the current strength for an extra four weeks, or step you back down. There is no rule saying you must move up on schedule. The schedule is a default, not a contract.

How providers decide when to move you up

Three signals tell a clinician whether to step up:

1. Goal not yet met. For type 2 diabetes, the target is usually A1C below 7.0% (or whatever individualized target your provider sets). For weight loss, the target is typically 5% to 15% reduction from baseline within six months. If the current dose isn't tracking toward the goal, step up.

2. Side effects are tolerable. If nausea, vomiting, diarrhea, or constipation are mild and improving week over week, step up at the four-week mark. If side effects are getting worse or staying severe, hold or step down.

3. The patient prefers the lower dose. Some patients reach a satisfying weight or A1C at 5 mg and choose to stay there indefinitely. That's a legitimate clinical choice. Maximum dose is not the same as best dose.

A 2024 real-world analysis (Karagiannis et al., Diabetes, Obesity and Metabolism) of 14,000 tirzepatide patients in U.S. claims data found that 38% remained at 5 mg or below at month 12, 41% reached 10 mg, and only 21% titrated to 15 mg. The majority of long-term users sit at 5 to 10 mg.

Side effects by dose

GI side effects are tirzepatide's signature, and they roughly track the dose-response curve. SURMOUNT-1 reported these incidences across the 72-week trial:

Two patterns to notice. First, the absolute incidence of nausea isn't dramatically higher at 15 mg than at 5 mg, because most nausea happens during titration, not at maintenance. Second, vomiting climbs more steeply with dose than nausea does, which is why providers slow titration in patients who report any vomiting at lower doses.

If you're concerned about which dose minimizes side effects while preserving benefit, see our guide on tirzepatide side effects by dose.

What the SURMOUNT and SURPASS trials showed at each dose

The SURMOUNT trials studied tirzepatide for chronic weight management. SURMOUNT-1 (Jastreboff et al., NEJM, 2022) is the headline trial, with 2,539 adults with obesity or overweight plus a comorbidity, no diabetes.

The SURPASS trials studied tirzepatide for type 2 diabetes. SURPASS-2 (Frias et al., NEJM, 2021) compared tirzepatide against semaglutide 1 mg.

The diminishing-returns shape is consistent across both indications. The biggest jump in benefit is from placebo to 5 mg. The next jump is from 5 to 10. The jump from 10 to 15 is smaller and may not justify the extra side effect burden for every patient.

When to slow down or hold a dose

Holding the current dose is the right move if:

• Nausea is causing you to skip meals or lose more weight than your provider targeted.
• You're vomiting more than once a week.
• Constipation has lasted more than 5 days despite hydration and fiber.
• You feel lightheaded or dehydrated.
• You're traveling and can't reliably store the next pen at 36 to 46°F.

Stepping down to the previous dose is the right move if:

• Side effects don't improve after a 4-week hold.
• You experience signs of dehydration, severe abdominal pain, or symptoms that suggest pancreatitis (sudden severe upper abdominal pain radiating to the back).
• You've lost weight too fast and your provider wants a slower trajectory.

Stopping entirely is the right move if your provider tells you to, or if you experience an allergic reaction (hives, swelling, breathing difficulty). Call 911 for the latter.

Mounjaro doses for type 2 diabetes vs. weight loss

The same six dose strengths apply to both indications. The difference is what's printed on the box and what insurance covers.

• Mounjaro is the brand-name version of tirzepatide for type 2 diabetes.
• Zepbound is the brand-name version of tirzepatide for chronic weight management. Same molecule. Same six doses. Different label.

Insurance plans almost always require the diagnosis code to match the brand. A type 2 diabetes prescription gets Mounjaro. A weight-loss prescription gets Zepbound. Patients sometimes ask to use Mounjaro for weight loss because their plan covers it for diabetes, but a non-diabetic patient with a Mounjaro prescription will typically be denied at the pharmacy counter.

For more on the brand split, see our guide to Mounjaro vs. Zepbound.

Compounded tirzepatide and how its doses compare

Compounded tirzepatide is not FDA-approved. It is the same active molecule, prepared by a state-licensed compounding pharmacy in response to an individual prescription. The doses parallel Mounjaro's six strengths, but it's drawn from a multi-dose vial with a U-100 insulin syringe rather than a pre-loaded pen.

For a typical 10 mg/mL compounded vial, the unit equivalents of each Mounjaro dose are:

Compounded tirzepatide is typically titrated on the same four-week schedule as Mounjaro. Some providers titrate more slowly when patients have a history of severe GI side effects on other GLP-1 medications. See our tirzepatide unit conversion guide for the full chart at every concentration.

FAQ

What are the six Mounjaro doses? 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, all delivered as a once-weekly subcutaneous injection. The 2.5 mg dose is a four-week starting dose, not a maintenance dose.

How long do you stay on each Mounjaro dose? A minimum of four weeks at each dose before stepping up. Longer is fine if side effects need more time to settle or if your current dose is meeting your A1C or weight goal.

Do you have to go all the way to 15 mg? No. Many patients stay long-term at 5 mg or 10 mg if their blood sugar or weight target is met. Real-world data shows about 38% of patients are at 5 mg or below at month 12, and only about 21% reach 15 mg.

What is the maximum Mounjaro dose? 15 mg once weekly. There is no approved dose above 15 mg, and the marginal benefit between 10 mg and 15 mg is smaller than the benefit between 5 mg and 10 mg.

What's the starting dose of Mounjaro? 2.5 mg once weekly for the first four weeks. This dose is subtherapeutic by design. Its purpose is to let your gut acclimate before the first effective dose at 5 mg.

Can you skip Mounjaro doses during titration? You can't skip from 2.5 mg straight to 10 mg, for example. Each four-week step exists to limit nausea and vomiting. Skipping doses produces more severe GI side effects and higher dropout rates.

What if I miss a Mounjaro dose? If your missed dose is within 4 days (96 hours) of the scheduled time, take it as soon as you remember and resume the original weekly schedule. If more than 4 days have passed, skip the missed dose and resume on your normal day. Don't double up.

Can you go down a Mounjaro dose? Yes. If side effects at a higher dose are unacceptable, your provider can step you back to the previous strength. The schedule is a default, not a contract.

How does Mounjaro dose affect weight loss? SURMOUNT-1 reported mean weight loss of 16.0% at 5 mg, 21.4% at 10 mg, and 22.5% at 15 mg over 72 weeks. Higher doses give more loss, but with diminishing returns above 10 mg.

Is 5 mg of Mounjaro enough for weight loss? Often, yes. SURMOUNT-1 showed 16.0% mean body weight loss at 72 weeks on 5 mg. For many patients, that's both their target and the dose they tolerate best.

What is the highest Mounjaro dose for diabetes? 15 mg once weekly is the maximum FDA-approved dose for type 2 diabetes. SURPASS-2 showed an A1C reduction of 2.30 percentage points at this dose.

How do compounded tirzepatide doses compare to Mounjaro doses? The active molecule and dose strengths match. The delivery is different: compounded tirzepatide comes in a multi-dose vial drawn with a U-100 insulin syringe, while Mounjaro comes in single-use auto-injector pens.

Can I take Mounjaro twice a week instead of once? No. Tirzepatide's half-life of about 5 days is built around once-weekly dosing. Splitting the dose changes the steady-state pharmacology and is not how the drug was studied or approved.

Author / review note

Reviewed by the FormBlends Medical Team. References include Jastreboff et al., New England Journal of Medicine, 2022 (SURMOUNT-1); Frias et al., New England Journal of Medicine, 2021 (SURPASS-2); Rosenstock et al., The Lancet, 2021 (SURPASS-1); Karagiannis et al., Diabetes, Obesity and Metabolism, 2024 (real-world tirzepatide titration patterns); and the Eli Lilly Mounjaro prescribing information (rev. 2024).

Sources

1. Jastreboff et al., New England Journal of Medicine, 2022 (SURMOUNT-1).
2. Frias et al., New England Journal of Medicine, 2021 (SURPASS-2).
3. Rosenstock et al., The Lancet, 2021 (SURPASS-1).
4. Karagiannis et al., Diabetes, Obesity and Metabolism, 2024 (real-world tirzepatide titration patterns).
5. The Eli Lilly Mounjaro prescribing information (rev. 2024).

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.